News Headlines Article

Deadly genetic heart condition leads Sanofi to $200M MyoKardia deal
San Francisco Chronicle

Startup MyoKardia Inc.’s focus on treatments for deadly genetic heart diseases has landed a potential $200 million collaboration with French drug maker Sanofi. The drug discovery and development deal, announced late Tuesday night, is significant for a couple of reasons. First and foremost, it underscores that startups with good science supporting big targets still can score substantial hookups with established biopharmaceutical players.